Surgical Management of Peyronie’s Disease

被引:0
作者
Uwais B. Zaid
Amjad Alwaal
Xiaoyu Zhang
Tom F. Lue
机构
[1] UCSF School of Medicine,Department of Urology
来源
Current Urology Reports | 2014年 / 15卷
关键词
Peyronie’s disease; Surgical management; Penile prosthesis; Tunical shortening;
D O I
暂无
中图分类号
学科分类号
摘要
Peyronie’s disease (PD) has a significant impact on the quality of life of both patients and their partners due to the compromised sexual function and physical deformation resulting from the condition. PD is a connective tissue disorder marked by fibrotic healing of the tunica albuginea, leading to penile deformities including curvature, shortening, loss of girth, hourglass appearance, and hinging. Despite the multiple medical therapies available, surgery is the gold standard of treatment once the plaque has stabilized. We present a review of the disease process, preoperative evaluation, operative planning, surgical treatments with outcomes and complications, and nascent developments in surgical management and graft development. Options include tunical lengthening procedures, tunical shortening procedures, and penile prosthesis. Decision-making is governed by degree of curvature, erectile function, and associated penile deformities. In cases with curvature of less than 60–70 degrees, adequate penile length, and no hourglass deformity, patients are candidates for tunical shortening procedures. Patients with curvature greater than 60–70 degrees, penile hourglass or hinge-destabilizing deformities, and adequate erectile function should be counseled with regard to tunical lengthening procedures. Patients with poor preoperative erectile function should undergo inflatable penile prosthesis placement, with possible secondary straightening procedures. Technique selection should be based upon surgeon preference, expertise, and experience, as evidence does not necessarily support one procedure over another.
引用
收藏
相关论文
共 397 条
[1]  
Nelson CJ(2013)Psychological impact of Peyronie's disease: A review J Sex Med 10 653-60
[2]  
Mulhall JP(2013)Surgery for Peyronie's disease Asian J Androl 15 27-34
[3]  
Levine LA(2010)The management of Peyronie's disease: Evidence-based 2010 guidelines J Sex Med 7 2359-74
[4]  
Larsen SM(2011)The association between Peyronie's and Dupuytren's disease Int J Impot Res 23 142-5
[5]  
Ralph D(2013)Understanding the course of Peyronie's disease Int J Clin Pract 67 781-8
[6]  
Gonzalez-Cadavid N(2010)Peyronie's disease following radical prostatectomy: Incidence and predictors J Sex Med 7 1254-61
[7]  
Mirone V(2005)Peyronie's disease in diabetic patients being screened for erectile dysfunction J Urol 174 1026-30
[8]  
Nugteren HM(1997)An animal model of Peyronie's-like condition associated with an increase of transforming growth factor beta mRNA and protein expression J Urol 158 2284-90
[9]  
Nijman JM(2009)IN-1130, a novel transforming growth factor-beta type I receptor kinase (activin receptor-like kinase 5) inhibitor, promotes regression of fibrotic plaque and corrects penile curvature in a rat model of Peyronie's disease J Sex Med 6 1284-96
[10]  
de Jong IJ(1997)Peyronie's disease is associated with an increase in transforming growth factor-beta protein expression J Urol 158 1391-4